Potential Impact of Menthol Ban in Cigarettes and E-cigarettes

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05259566
Collaborator
(none)
150
1
3
42
3.6

Study Details

Study Description

Brief Summary

Menthol cigarette use remains a major public health problem and the FDA has proposed to ban menthol in cigarettes. However, additional evidence is needed to understand whether menthol flavor in e-cigarettes is important for harm reduction among menthol cigarette smokers in the context of a menthol cigarette ban. The primary aim of this project is to understand how the availability of menthol vs tobacco flavor e-cigarettes influences switching and reduces smoking behavior among adults who currently smoke menthol cigarettes to understand the potential effects in the context of a ban of menthol cigarettes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: menthol ban in cigarettes only
  • Behavioral: total menthol ban
N/A

Detailed Description

Menthol cigarette use remains a major public health problem and the FDA has proposed to ban menthol in cigarettes. However, additional evidence is needed to understand whether menthol flavor in e-cigarettes is important for harm reduction among menthol cigarette smokers in the context of a menthol cigarette ban.

The primary aim of this project is to understand how the availability of menthol vs tobacco flavor e-cigarettes influences switching and reduces smoking behavior among adults who currently smoke menthol cigarettes to understand the potential effects in the context of a ban of menthol cigarettes. The secondary aim of this project is to understand whether smoking behavior outcomes differ by race to understand the impact of these potential menthol ban policies on addressing tobacco-related health disparities.

This single site study will take place over a 4 year study period; approximately 14 weeks for each participant's completion.

150 adults who currently smoke menthol cigarettes will be enrolled and prospectively randomized using a randomization ratio of 1:1:1 to 1 of 3 groups (N=50 per group). Following an initial baseline period where participants have access to their usual menthol cigarettes (Phase I), participants will receive tobacco products to use for 8 weeks based on their assigned group modeling 3 possible regulatory scenarios (Phase II): 1) no menthol ban (menthol cigarettes and e-cigarettes available), 2) menthol ban in cigarettes only (non-menthol cigarettes and menthol e-cigarettes available), 3) menthol ban in both cigarettes and e-cigarettes (non-menthol cigarettes and tobacco e-cigarettes available). A follow-up survey at week 12 will assess tobacco use outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Evaluating the Potential Impact of a Menthol Ban in Cigarettes and E-cigarettes Among Current Menthol Smokers
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Mar 31, 2026

Arms and Interventions

Arm Intervention/Treatment
No Intervention: no menthol ban

usual menthol cigarettes and menthol flavored e-cigarette available

Experimental: menthol ban in cigarettes only

non-menthol cigarettes and menthol flavored e-cigarette available

Behavioral: menthol ban in cigarettes only
menthol ban in cigarettes only, menthol available in e-cigarette

Experimental: menthol ban in both cigarettes and e-cigarettes

non-menthol cigarettes and tobacco flavored e-cigarette available,

Behavioral: total menthol ban
menthol ban in both cigarettes and e-cigarettes

Outcome Measures

Primary Outcome Measures

  1. Average number of cigarettes smoked per day in the past week to evaluate changes in smoking behavior [From Week 0 to week 8]

    Participants will report the total number of cigarettes consumed each day using the well-validated timeline follow-back (TLFB) interview methods to assess change.

Secondary Outcome Measures

  1. Percent days smoke-free [From Week 0 to week 8]

    Participants will report the number of smoke free days over the 8 week study period. Percent days smoke-free will be determined using the TLFB interview methods.

  2. Changes in nicotine dependence using the Nicotine Dependence for Daily Smokers Scale [From Week 0 to week 8]

    Changes in nicotine dependence will be measured using the Nicotine Dependence for Daily Smokers Scale from the NIH Patient Reported Outcome Measure Information System (PROMIS) bank. Scores are averaged across 4 items, min=1, max=5. Higher scores indicate greater nicotine dependence.

  3. Change in Quitting motivation and confidence [Week 0 and week 8]

    Quitting motivation and confidence will be assessed using the PhenX Toolkit using the items "How motivated are you to quit smoking?" and "How confident are you that you could quit smoking if you tried?" rated from 1 (not at all) to 10 (extremely).

  4. Quit intentions using the Stages of Change Assessment [Week 0 and week 8]

    Participants will report their plans to quit smoking in the next 30 days based on Stages of Change Assessment, on a scale from 0 (I have absolutely no intention of quitting smoking) to 10 (I have made a firm decision to quit in the next 30 days). Higher scores indicate the more intention to quit.

Other Outcome Measures

  1. Percent days of e-cigarette use [From Week 0 to week 8]

    Participants will report the number of days using the e-cigarette over the 8 week study period using the TLFB interview

  2. Number of quit attempts during follow-up [Week 12]

    Number of quit attempts at the 12-week follow-up, measured by the TLFB interview methods.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Provision of signed and dated informed consent form

  • Age 21 or older

  • Able to read English

  • Currently smoking cigarettes

  • Past experience and willing to use e-cigarettes

  • In good general health

Exclusion Criteria:
  • Seeking smoking cessation treatment

  • Serious psychiatric or medical condition

  • Use of other drugs

  • Unable or unwilling to complete study protocol

  • Contraindications for study procedures based on medical history

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yale University New Haven Connecticut United States 06520

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Krysten Bold, PhD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT05259566
Other Study ID Numbers:
  • 2000032211
First Posted:
Feb 28, 2022
Last Update Posted:
Aug 23, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2022